JP2008506710A5 - - Google Patents

Download PDF

Info

Publication number
JP2008506710A5
JP2008506710A5 JP2007521685A JP2007521685A JP2008506710A5 JP 2008506710 A5 JP2008506710 A5 JP 2008506710A5 JP 2007521685 A JP2007521685 A JP 2007521685A JP 2007521685 A JP2007521685 A JP 2007521685A JP 2008506710 A5 JP2008506710 A5 JP 2008506710A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
aralkyl
pharmaceutical composition
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007521685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008506710A (ja
JP5618461B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/025192 external-priority patent/WO2006020048A2/en
Publication of JP2008506710A publication Critical patent/JP2008506710A/ja
Publication of JP2008506710A5 publication Critical patent/JP2008506710A5/ja
Application granted granted Critical
Publication of JP5618461B2 publication Critical patent/JP5618461B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007521685A 2004-07-16 2005-07-15 癌の治療のための化合物および方法 Expired - Fee Related JP5618461B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58859604P 2004-07-16 2004-07-16
US60/588,596 2004-07-16
PCT/US2005/025192 WO2006020048A2 (en) 2004-07-16 2005-07-15 Compounds and methods for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011227543A Division JP2012051919A (ja) 2004-07-16 2011-10-17 癌の治療のための化合物および方法

Publications (3)

Publication Number Publication Date
JP2008506710A JP2008506710A (ja) 2008-03-06
JP2008506710A5 true JP2008506710A5 (enExample) 2008-07-31
JP5618461B2 JP5618461B2 (ja) 2014-11-05

Family

ID=35414967

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007521685A Expired - Fee Related JP5618461B2 (ja) 2004-07-16 2005-07-15 癌の治療のための化合物および方法
JP2011227543A Withdrawn JP2012051919A (ja) 2004-07-16 2011-10-17 癌の治療のための化合物および方法
JP2014037807A Expired - Lifetime JP5745660B2 (ja) 2004-07-16 2014-02-28 癌の治療のための化合物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011227543A Withdrawn JP2012051919A (ja) 2004-07-16 2011-10-17 癌の治療のための化合物および方法
JP2014037807A Expired - Lifetime JP5745660B2 (ja) 2004-07-16 2014-02-28 癌の治療のための化合物および方法

Country Status (11)

Country Link
US (2) US7405314B2 (enExample)
EP (1) EP1771459A2 (enExample)
JP (3) JP5618461B2 (enExample)
KR (5) KR20130001323A (enExample)
CN (3) CN101076533B (enExample)
AU (1) AU2005274926B2 (enExample)
CA (2) CA2574032C (enExample)
HK (1) HK1204476A1 (enExample)
IL (2) IL180729A (enExample)
TW (3) TW201440760A (enExample)
WO (1) WO2006020048A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2462932A1 (en) 2002-01-07 2012-06-13 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
US7628810B2 (en) 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
ES2532666T3 (es) 2005-07-29 2015-03-30 Solasia Pharma K.K. Compuestos y métodos para el tratamiento del cáncer
CN104109177A (zh) * 2006-01-13 2014-10-22 得克萨斯州A&M大学系统 用于治疗癌症的化合物和方法
RU2318519C2 (ru) * 2006-03-06 2008-03-10 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ химиотерапии острого лейкоза
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
KR20100100835A (ko) 2007-11-02 2010-09-15 지오팜 온콜로지 인코포레이티드 유기 비소제와의 병용 요법
CN104592302A (zh) * 2007-12-12 2015-05-06 日本苏爱康制药有限公司 用于治疗癌症的化合物和方法
RU2534606C2 (ru) 2008-08-20 2014-11-27 Зайофарм Онколоджи, Инк. Мышьякорганические соединения и способы лечения рака
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
CA2770735C (en) 2009-08-13 2017-07-18 Acufocus, Inc. Masked intraocular implants and lenses
US10004593B2 (en) 2009-08-13 2018-06-26 Acufocus, Inc. Intraocular lens with elastic mask
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
EP2785296B1 (en) 2011-12-02 2018-06-20 AcuFocus, Inc. Ocular mask having selective spectral transmission
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
TWI617305B (zh) * 2013-12-05 2018-03-11 蘇愛康制藥有限公司 治療癌症的化合物及其應用程序
GB201418491D0 (en) * 2014-10-17 2014-12-03 Monfort University De Compounds
WO2016081493A1 (en) 2014-11-19 2016-05-26 Acufocus, Inc. Fracturable mask for treating presbyopia
WO2017062316A1 (en) 2015-10-05 2017-04-13 Acufocus, Inc. Methods of molding intraocular lenses
EP3384342B1 (en) 2015-11-24 2021-08-25 AcuFocus, Inc. Toric small aperture intraocular lens with extended depth of focus
CN105330701B (zh) * 2015-11-27 2017-05-31 昆明医科大学 一种含砷化合物及其制备方法和应用
EP3790508A4 (en) 2018-05-09 2022-02-09 AcuFocus, Inc. INTRAOCULAR IMPLANT WITH REMOVABLE OPTICS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018798A1 (en) * 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) * 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
CN1443064A (zh) * 2000-04-26 2003-09-17 俄勒冈健康科学大学 施用含硫醇化学保护化合物的方法
EP2462932A1 (en) * 2002-01-07 2012-06-13 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物

Similar Documents

Publication Publication Date Title
JP2008506710A5 (enExample)
CA2574032A1 (en) Compounds and methods for the treatment of cancer
JP7121660B2 (ja) 癌を処置するためのezh2阻害剤の使用
RU97100718A (ru) Новые соединения, способы их получения и противоопухолевые средства
CA2619828A1 (en) Methods to enhance chemotherapy
JP2007501809A5 (enExample)
JP2022501344A (ja) 新規キナゾリンegfr阻害剤
JP2017532316A5 (enExample)
CZ166893A3 (en) Pharmaceutical composition
ES2312978T3 (es) Potenciador del efecto antitumoral y agente antitumoral.
JP2005531563A5 (enExample)
US20100227831A1 (en) Compositions and methods for cancer treatment
CA2410160C (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
JPWO1992004028A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
ES2317913T3 (es) Tratamiento antitumoral combinado que comprende un derivado de la distamicina sustituida por acriloilo y un antimetabolito.
RU2009102241A (ru) Производные камптотецина с противоопухолевой активностью
JP2010500971A5 (enExample)
CA2427569A1 (en) Selective glucocorticoid receptor agonists
JP2011502985A5 (enExample)
JP2013227347A5 (enExample)
WO2013137433A1 (ja) 3剤を組み合わせた新規な抗腫瘍剤
PT1757283E (pt) Potenciador do efeito antitumoral, agente antitumoral e método para a terapia do cancro
JP2003535874A5 (enExample)
US20050101534A1 (en) Compositions and methods for treating or preventing hearing impairment
JP2007500205A5 (enExample)